Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors

Thomas E. Merchant, Ciara J. Gould, Xiaoping Xiong, Nicole Robbins, Junhong Zhu, David L. Pritchard, Raja Khan, Richard L. Heideman, Matthew J. Krasin, Larry E. Kun

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Purpose Central nervous system (CNS) irradiation can cause sensorineural hearing loss. The relationship between the dose to the cochlea and the development of hearing loss is unknown. Conformal radiation therapy (CRT) techniques facilitate accurate cochlear dosimetry. We modeled hearing threshold levels (HTL) after CRT in children with localized primary brain tumors (ependymoma, low- or high-grade astrocytoma, craniopharyngioma, or CNS germinoma) by using cochlear dose and clinical variables. Patients and methods We evaluated 72 children (median age, 9.5 years) with audiograms before and every 6 months after CRT (median follow-up, 16.6 months; range, 4.3-42.6 months). We used a mixed-effects model to predict change in hearing for each ear as a function of time, cochlear dose, and clinical variables. Results Hearing was affected the greatest in patients with CSF shunts and pre-CRT ototoxic chemotherapy, enhanced by cochlear dose, and was more prominent on the right side. Hearing impairment after CRT alone occurred at low and intermediate frequencies in patients with shunts and supratentorial tumors when the cochlear dose exceeded 32 Gy. Patients with shunts and central supratentorial tumors developed intermediate-frequency hearing loss after CRT alone regardless of dose. Conclusions Hearing loss during the first 4 years after CRT alone is uncommon, although patients with shunts and supratentorial tumors appear to be at increased risk for low- and intermediate-frequency effects. CSF shunting and increased cochlear dose enhance the effect of ototoxic chemotherapy. If possible, the average cochlear dose should be <32 Gy over a 6-week course of treatment until more specific dose data become available.

Original languageEnglish (US)
Pages (from-to)1194-1207
Number of pages14
JournalInternational Journal of Radiation Oncology Biology Physics
Volume58
Issue number4
DOIs
StatePublished - Mar 15 2004

Fingerprint

Cochlea
Brain Neoplasms
brain
tumors
Radiotherapy
radiation therapy
dosage
irradiation
Supratentorial Neoplasms
auditory defects
Hearing Loss
shunts
hearing
intermediate frequencies
Hearing
central nervous system
chemotherapy
Central Nervous System
grade
Germinoma

Keywords

  • Chemotherapy
  • Craniopharyngioma
  • Ependymoma
  • Hearing
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. / Merchant, Thomas E.; Gould, Ciara J.; Xiong, Xiaoping; Robbins, Nicole; Zhu, Junhong; Pritchard, David L.; Khan, Raja; Heideman, Richard L.; Krasin, Matthew J.; Kun, Larry E.

In: International Journal of Radiation Oncology Biology Physics, Vol. 58, No. 4, 15.03.2004, p. 1194-1207.

Research output: Contribution to journalArticle

Merchant, TE, Gould, CJ, Xiong, X, Robbins, N, Zhu, J, Pritchard, DL, Khan, R, Heideman, RL, Krasin, MJ & Kun, LE 2004, 'Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors', International Journal of Radiation Oncology Biology Physics, vol. 58, no. 4, pp. 1194-1207. https://doi.org/10.1016/j.ijrobp.2003.07.008
Merchant, Thomas E. ; Gould, Ciara J. ; Xiong, Xiaoping ; Robbins, Nicole ; Zhu, Junhong ; Pritchard, David L. ; Khan, Raja ; Heideman, Richard L. ; Krasin, Matthew J. ; Kun, Larry E. / Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. In: International Journal of Radiation Oncology Biology Physics. 2004 ; Vol. 58, No. 4. pp. 1194-1207.
@article{f26b9670b1544f90ab00476a798762e3,
title = "Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors",
abstract = "Purpose Central nervous system (CNS) irradiation can cause sensorineural hearing loss. The relationship between the dose to the cochlea and the development of hearing loss is unknown. Conformal radiation therapy (CRT) techniques facilitate accurate cochlear dosimetry. We modeled hearing threshold levels (HTL) after CRT in children with localized primary brain tumors (ependymoma, low- or high-grade astrocytoma, craniopharyngioma, or CNS germinoma) by using cochlear dose and clinical variables. Patients and methods We evaluated 72 children (median age, 9.5 years) with audiograms before and every 6 months after CRT (median follow-up, 16.6 months; range, 4.3-42.6 months). We used a mixed-effects model to predict change in hearing for each ear as a function of time, cochlear dose, and clinical variables. Results Hearing was affected the greatest in patients with CSF shunts and pre-CRT ototoxic chemotherapy, enhanced by cochlear dose, and was more prominent on the right side. Hearing impairment after CRT alone occurred at low and intermediate frequencies in patients with shunts and supratentorial tumors when the cochlear dose exceeded 32 Gy. Patients with shunts and central supratentorial tumors developed intermediate-frequency hearing loss after CRT alone regardless of dose. Conclusions Hearing loss during the first 4 years after CRT alone is uncommon, although patients with shunts and supratentorial tumors appear to be at increased risk for low- and intermediate-frequency effects. CSF shunting and increased cochlear dose enhance the effect of ototoxic chemotherapy. If possible, the average cochlear dose should be <32 Gy over a 6-week course of treatment until more specific dose data become available.",
keywords = "Chemotherapy, Craniopharyngioma, Ependymoma, Hearing, Radiotherapy",
author = "Merchant, {Thomas E.} and Gould, {Ciara J.} and Xiaoping Xiong and Nicole Robbins and Junhong Zhu and Pritchard, {David L.} and Raja Khan and Heideman, {Richard L.} and Krasin, {Matthew J.} and Kun, {Larry E.}",
year = "2004",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2003.07.008",
language = "English (US)",
volume = "58",
pages = "1194--1207",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors

AU - Merchant, Thomas E.

AU - Gould, Ciara J.

AU - Xiong, Xiaoping

AU - Robbins, Nicole

AU - Zhu, Junhong

AU - Pritchard, David L.

AU - Khan, Raja

AU - Heideman, Richard L.

AU - Krasin, Matthew J.

AU - Kun, Larry E.

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Purpose Central nervous system (CNS) irradiation can cause sensorineural hearing loss. The relationship between the dose to the cochlea and the development of hearing loss is unknown. Conformal radiation therapy (CRT) techniques facilitate accurate cochlear dosimetry. We modeled hearing threshold levels (HTL) after CRT in children with localized primary brain tumors (ependymoma, low- or high-grade astrocytoma, craniopharyngioma, or CNS germinoma) by using cochlear dose and clinical variables. Patients and methods We evaluated 72 children (median age, 9.5 years) with audiograms before and every 6 months after CRT (median follow-up, 16.6 months; range, 4.3-42.6 months). We used a mixed-effects model to predict change in hearing for each ear as a function of time, cochlear dose, and clinical variables. Results Hearing was affected the greatest in patients with CSF shunts and pre-CRT ototoxic chemotherapy, enhanced by cochlear dose, and was more prominent on the right side. Hearing impairment after CRT alone occurred at low and intermediate frequencies in patients with shunts and supratentorial tumors when the cochlear dose exceeded 32 Gy. Patients with shunts and central supratentorial tumors developed intermediate-frequency hearing loss after CRT alone regardless of dose. Conclusions Hearing loss during the first 4 years after CRT alone is uncommon, although patients with shunts and supratentorial tumors appear to be at increased risk for low- and intermediate-frequency effects. CSF shunting and increased cochlear dose enhance the effect of ototoxic chemotherapy. If possible, the average cochlear dose should be <32 Gy over a 6-week course of treatment until more specific dose data become available.

AB - Purpose Central nervous system (CNS) irradiation can cause sensorineural hearing loss. The relationship between the dose to the cochlea and the development of hearing loss is unknown. Conformal radiation therapy (CRT) techniques facilitate accurate cochlear dosimetry. We modeled hearing threshold levels (HTL) after CRT in children with localized primary brain tumors (ependymoma, low- or high-grade astrocytoma, craniopharyngioma, or CNS germinoma) by using cochlear dose and clinical variables. Patients and methods We evaluated 72 children (median age, 9.5 years) with audiograms before and every 6 months after CRT (median follow-up, 16.6 months; range, 4.3-42.6 months). We used a mixed-effects model to predict change in hearing for each ear as a function of time, cochlear dose, and clinical variables. Results Hearing was affected the greatest in patients with CSF shunts and pre-CRT ototoxic chemotherapy, enhanced by cochlear dose, and was more prominent on the right side. Hearing impairment after CRT alone occurred at low and intermediate frequencies in patients with shunts and supratentorial tumors when the cochlear dose exceeded 32 Gy. Patients with shunts and central supratentorial tumors developed intermediate-frequency hearing loss after CRT alone regardless of dose. Conclusions Hearing loss during the first 4 years after CRT alone is uncommon, although patients with shunts and supratentorial tumors appear to be at increased risk for low- and intermediate-frequency effects. CSF shunting and increased cochlear dose enhance the effect of ototoxic chemotherapy. If possible, the average cochlear dose should be <32 Gy over a 6-week course of treatment until more specific dose data become available.

KW - Chemotherapy

KW - Craniopharyngioma

KW - Ependymoma

KW - Hearing

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=12144286160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144286160&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2003.07.008

DO - 10.1016/j.ijrobp.2003.07.008

M3 - Article

C2 - 15001264

AN - SCOPUS:12144286160

VL - 58

SP - 1194

EP - 1207

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -